1.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 and under at diagnosis Sponsor: NCI, Other Protocol IDs: CDR0000573996, COG-AALL0631, AALL0631, NCT00557193
|
|
2.
|
Phase: Phase III Type: Behavioral study, Treatment Status: Active Age: 1 to under 31 Sponsor: NCI Protocol IDs: NCI-2009-00307, AALL0434, CDR0000514500, COG-AALL0434, U01CA98543, NCT00408005
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: T2009-003, NCT01483690
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 1 to 31 Sponsor: NCI, Other Protocol IDs: CDR0000638413, COG-AALL07P1, AALL07P1, NCT00873093
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: 8 to 75 Sponsor: NHLBI Protocol IDs: 090087, 09-H-0087, NCT00859586
|
|
6.
|
Phase: Phase II Type: Treatment Status: Active Age: 12 to 40 Sponsor: Other Protocol IDs: 2006-0375, NCT00866749
|
|
7.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2009-0717, NCT01094860
|
|
8.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 months to 21 years Sponsor: NCI Protocol IDs: NCI-2011-02679, ADVL1114, COG_ADVL1114, CDR0000703889, U01CA097452, NCT01403415
|
|
9.
|
Phase: No phase specified Type: Treatment Status: Active Age: 365 days and under Sponsor: Other Protocol IDs: CDR0000570260, DCOG-INTERFANT-06, EUDRACT-2005-004599-19, CCLG-LK-2006-10, NCT00550992
|
|
10.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: SIR-MO-1101, 2012-0361, NCT01658007
|